Promising combo tackles rare sarcomas in early trial
NCT ID NCT03123276
First seen Feb 21, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This early-phase study tested whether combining the immunotherapy drug pembrolizumab with the chemotherapy gemcitabine is safe for people with two rare types of soft tissue sarcoma (leiomyosarcoma and undifferentiated pleomorphic sarcoma). 25 participants with advanced or inoperable disease received the combination. The main goal was to find the safest dose and check for side effects, while also looking at how well the tumors responded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Royal Marsden
London, United Kingdom
Conditions
Explore the condition pages connected to this study.